Factors affecting work-related non-fatal injuries among aged workers in South Korea

IntroductionThe objective of this paper is to investigate whether an aging workforce is associated with an increase in work-related non-fatal injuries and to explore the underlying reasons for this potential increase.MethodsAged workers were defined as those who were at least 55-years-old. Work-related non-fatal injuries were assessed in aged and young workers who were registered with the workers’ compensation system from 2017 to 2021 of South Korea.ResultsThe mean estimated rate of work-related non-fatal injuries of aged workers (0.88/100) was about 2.5-times higher than that of younger workers (0.35/100). Most work-related non-fatal injuries in the older adults were in individuals working in the “construction sector” (36.0%), those with “elementary occupations (unskilled workers)” (45.0%), and those with employment status of “daily worker” (44.0%). “Trip & slip” (28.7%) and “falling” (19.6%) were more frequent types of work-related non-fatal injuries in aged workers relative to young workers. The category of “buildings, structures, and surfaces” was a more frequent cause of work-related non-fatal injuries in aged workers than young workers.DiscussionThe incidence of non-fatal work-related injuries is higher among aged workers compared to their younger counterparts. The increased occurrence of aged workers participating in precarious employment and jobs, along with the greater physical vulnerability, is likely the cause of their higher rate of work-related non-fatal injuries

Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011–2013

Abstracts Background Clinical trial globalization is a major trend for industry-sponsored clinical trials. There has been a shift in clinical trial sites towards emerging regions of Eastern Europe, Latin America, Asia, the Middle East, and Africa. Our study objectives were to evaluate the current characteristics of clinical trials and to find out the associated multiple factors which could explain clinical trial globalization and its implications for clinical trial globalization in 2011–2013. Methods The data elements of “phase,” “recruitment status,” “type of sponsor,” “age groups,” and “design of trial” from 30 countries were extracted from the ClinicalTrials.gov website. Ten continental representative countries including the USA were selected and the design elements were compared to those of the USA. Factors associated with trial site distribution were chosen for a multilinear regression analysis. Results The USA, Germany, France, Canada, and United Kingdom were the “top five” countries which frequently held clinical trials. The design elements from nine continental representative countries were quite different from those of the USA; phase 1 trials were more prevalent in India (OR 1.517, p < 0.001) while phase 3 trials were much more prevalent in all nine representative countries than in the USA. A larger number of “child” age group trials was performed in Poland (OR 1.852, p < 0.001), Israel (OR 1.546, p = 0.005), and South Africa (OR 1.963, p < 0.001) than in the USA. Multivariate analysis showed that health care expenditure per capita, Economic Freedom Index, Human Capital Index, and Intellectual Property Rights Index could explain the variance of regional distribution of clinical trials by 63.6%. Conclusions The globalization of clinical trials in the emerging regions of Asia, South Africa, and Eastern Europe developed in parallel with the factors of economic drive, population for recruitment, and regulatory constraints

Additional file 3: of Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011–2013

Number values of associated factors (explanatory variables) considered in regression analysis on clinical trial site distribution. (DOCX 16 kb

Additional file 2: of Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011–2013

The geographical distribution and characteristics of drug interventional clinical trial in the top 30 countries worldwide, 2011–2013. (DOCX 29 kb